Negotiations are continuing between the Council, the European Parliament and the European Commission on the proposal for a regulation on advanced therapy medicinal products. The EP's vote at first reading, scheduled for the mid-March plenary session, has been postponed until April at the earliest. The Commission's proposal aims to create a single regulatory framework that entails a centralised authorisation procedure, via the European Agency for Evaluation of Medicinal Products (EMEA) in London, for the development of gene therapy, cell therapy and tissue engineering, which are promising for the treatment of genetic diseases, rare cancers and serious burn cases. The three institutions are still working on the scope of the new...
ADVANCED THERAPIES : VOTE POSTPONED AGAINST BACKDROP OF DEBATE ON ETHICS
From: European Social Policy
Document Type: Article
Length: 442 words
Lexile Measure: 1310L
Article Preview :
Copyright: COPYRIGHT 2007 Europolitics